Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trials

Experimental and Therapeutic Medicine

Volumn 3, Issue 1, 2012, Pages 134-140

  Matsuda, Ayako ^a   Yamaoka, Kazue ^b   Tango, Toshiro ^c  

^a NATIONAL CANCER CENTER   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c Center for Medical Statistics   (Japan)

Author keywords

Advanced non small cell lung cancer; Chemotherapy; Meta analysis; Palliative care; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DYSPNEA; FATIGUE; HUMAN; INFORMATION RETRIEVAL; INSOMNIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84855361811     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.368     Document Type: Article

References (36)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Novello S and Le Chevalier T: Chemotherapy for non-small-cell lung cancer. Part 1. Early-stage disease. Oncology 17: 357-364, 2003
3. De Petris L, Crinò L, Scagliotti GV, et al: Treatment of advanced non-small cell lung cancer. Ann Oncol 17: ii36-ii41, 2006.
4. Gridelli C, Perrone F, Nelli F, et al: Quality of life in lung cancer patients. Ann Oncol 12: S21-S25, 2001.
5. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15: 2996-3018, 1997.
6. Persson C, Ostlund U, Wennman-Larsen A, Wengström Y and Gustavsson P: Health-related quality of life in significant others of patients dying from lung cancer. Palliat Med 22: 239-247, 2008.
7. Albers G, Echteld MA, de Vet HC, et al: Evaluation of quality of life measures for use in palliative care: systematic review. Palliat Med 24: 17-34, 2010.
8. Beitz J, Gnecco C and Justice R: Quality of life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 20: 7-9, 1996.
9. Harper P, Plunket T and Khayat D: Quality trials and quality of life in non-small cell lung cancer. J Clin Oncol 21: 3007-3008, 2003.
10. Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 3852-3859, 2004.
11. Ardizzoni A, Boni L, Tiseo M, et al: Cisplatin- versus carboplatin-based chemotherapy in frst-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99: 847-857, 2007.
12. Jiang J, Liang X, Zhou X, et al: A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57: 348-358, 2007.
13. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 364-376, 1993.
14. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12: 199-220, 1995.
15. James K, Eisenhauer E, Christian M, et al: Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 17: 523-528, 1999.
16. Tango T: An introduction to meta-analysis. In: Medical Statistical Science Series 4. Asakura bookstore, Tokyo, pp99-101, 2009.
17. Whitehead A: Meta-analysis of Controlled Clinical Trials. John Wiley & Sons, Ltd., Chichester, pp237-240, 2002.
18. Scott NW, Fayers PM, Aaronson NK, et al: EORTC QLQ-C30 Reference Values. July, 2008 [updated August 6, 2011]. http://groups.eortc.be/qol/downloads/reference_values_manual2008.pdf.
19. Petitti DB: Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. Oxford University Press, Oxford, New York, pp116-117, 2010.
20. Spector P: An Introduction to S and S-Plus. Duxbury Press, Belmont, CA, 1994.
21. Rosell R, Gatzemeier U, Betticher DC, et al: Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13: 1539-1549, 2002.
22. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-4291, 2002.
23. Danson S, Middleton MR, O'Byrne KJ, et al: Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98: 542-553, 2003.
24. Paccagnella A, Favaretto A, Oniga F, et al: Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43: 83-91, 2004.
25. Rudd RM, Gower NH, Spiro SG, et al: Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23: 142-153, 2005.
26. Booton R, Lorigan P, Anderson H, et al: A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 17: 1111-1119, 2006.
27. Hotta K and Matsuo K: Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer. J Thorac Oncol 2: 96, 2007.
28. Goffin J, Lacchetti C, Ellis PM, et al: First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5: 260-274, 2010.
29. Morita S, Kobayashi K, Eguchi K, et al: Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 33: 470-476, 2003.
30. Buccheri G, Vola F and Ferrigno D: Aspects of quality-of-life in patients with lung-cancer - a 3 observer evaluation study. Int J Oncol 2: 537-544, 1993.
31. Holzner B, Bode RK, Hahn EA, et al: Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer 42: 3169-3177, 2006.
32. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188-3194, 1999.
33. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631, 2000.
34. Hollen PJ and Gralla RJ: Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 23: 31-40, 1996.
35. Editorial: Quality of life and clinical trials. Lancet 346: 1-2, 1995.
36. Thatcher N, Hopwood P and Anderson H: Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer 33: 8-13, 1997.